End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
14.48 USD | -0.14% | +6.08% | +26.13% |
04-30 | Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals | MT |
04-30 | Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent | MT |
Sales 2024 * | 356M 28.35B | Sales 2025 * | 606M 48.32B | Capitalization | 4.06B 323B |
---|---|---|---|---|---|
Net income 2024 * | -149M -11.87B | Net income 2025 * | 30M 2.39B | EV / Sales 2024 * | 15.5 x |
Net Debt 2024 * | 1.46B 116B | Net Debt 2025 * | 1.28B 102B | EV / Sales 2025 * | 8.79 x |
P/E ratio 2024 * |
-24.3
x | P/E ratio 2025 * |
140
x | Employees | 999 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 27.24% |
Latest transcript on Alvotech
1 day | -0.14% | ||
1 week | +6.08% | ||
Current month | -0.14% | ||
1 month | +27.02% | ||
3 months | -7.77% | ||
6 months | +62.70% | ||
Current year | +26.13% |
Managers | Title | Age | Since |
---|---|---|---|
Vilhelm Wessman
CEO | Chief Executive Officer | 54 | 01/11/18 |
Joel Morales
DFI | Director of Finance/CFO | 46 | 31/01/20 |
Giedrius Zunda
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Linda McGoldrick
BRD | Director/Board Member | 68 | 15/06/22 |
Helga Zharov
LAW | General Counsel | 57 | 30/04/20 |
Vilhelm Wessman
CEO | Chief Executive Officer | 54 | 01/11/18 |
Date | Price | Change | Volume |
---|---|---|---|
02/05/24 | 14.51 | +0.21% | 231,629 |
01/05/24 | 14.48 | -0.14% | 118,095 |
30/04/24 | 14.5 | +1.97% | 224,692 |
29/04/24 | 14.22 | +0.49% | 39,632 |
26/04/24 | 14.15 | +3.66% | 248,476 |
End-of-day quote Nasdaq, May 30, 2024
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+26.13% | 4.05B | |
+26.28% | 42.68B | |
-3.99% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+6.36% | 24.94B | |
-21.47% | 18.96B | |
+27.58% | 12.3B | |
-2.75% | 11.95B | |
-2.02% | 11.55B |
- Stock Market
- Equities
- ALVO Stock